Isoprenaline Hydrochloride Monico (Isoprenaline Hydrochloride)

The drug acts as a non‑selective agonist at β1 and β2 adrenergic receptors. Stimulation of β1 receptors in the heart increases pacemaker activity and contractile force, while β2 receptor activation in the lungs leads to smooth‑muscle relaxation and bronchodilation. This dual action supports both cardiac output and airway patency.

Dosing of Isoprenaline Hydrochloride Monico is individualized and determined by the prescribing clinician based on the patient’s condition, route of administration, and response. The prescriber will calculate the appropriate infusion rate or bolus amount and adjust it according to clinical monitoring.

Safety data for Isoprenaline Hydrochloride in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with selective β1‑agonists such as dobutamine, Isoprenaline Hydrochloride has a broader β‑adrenergic profile, offering stronger chronotropic effects and additional bronchodilation. This makes it useful in combined cardiac and respiratory emergencies, though its non‑selectivity can increase the risk of tachyarrhythmias.

The product should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Vials must be inspected for particulate matter before use and kept out of reach of children.

Isoprenaline Hydrochloride is supplied as a sterile injectable solution and may be given intravenously, intramuscularly, or subcutaneously. Administration is performed by qualified healthcare personnel, with dosing titrated to achieve the desired heart rate or bronchodilatory response while monitoring vital signs.

Serious risks include life‑threatening arrhythmias, myocardial ischemia, severe hypotension, and anaphylactic reactions. Continuous cardiac monitoring and readiness to manage acute adverse events are essential during administration, especially in patients with underlying heart disease.

Patients with uncontrolled hypertension, severe coronary artery disease, recent myocardial infarction, or known hypersensitivity to the drug should not receive Isoprenaline Hydrochloride. Additionally, concurrent use of non‑selective beta‑blockers is contraindicated because it can negate therapeutic effects and precipitate adverse outcomes.